| |
| |
|
| Insider
Information: |
Kayyem Jon Faiz |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
375,074 |
|
|
Indirect Shares
|
13,968,279 |
|
|
| Direct
Value |
$4,750,833 |
|
|
|
Indirect Value
|
$17,161,998 |
|
|
| Total
Shares |
14,343,353 |
|
|
| Total
Value |
$21,912,830 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Aeolus Pharmaceuticals Inc |
AOLS |
10% Owner |
|
0 |
2006-06-05 |
9,800,000 |
Premium* |
|
|
Genmark Diagnostics, Inc. |
GNMK |
SVP, Research & Develo... |
2018-02-02 |
197,622 |
2018-02-02 |
713,893 |
Premium* |
|
|
Inhibrx, Inc. |
INBX |
Director |
2022-08-02 |
0 |
2023-01-23 |
3,274,301 |
Premium* |
|
|
Biodesix Inc |
BDSX |
|
2023-08-03 |
177,452 |
2023-08-03 |
180,085 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
90 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AOLS |
Aeolus Pharmaceuticals In... |
10% Owner |
– – • |
2006-06-05 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
9,800,000 |
|
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
President & CEO |
• • – |
2010-06-03 |
4 |
A |
$0.00 |
$0 |
I/I |
505,893 |
319,308 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• • – |
2011-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,000 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• • – |
2011-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
19,585 |
30,585 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• – – |
2012-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
64,375 |
94,960 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• – – |
2013-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
19,053 |
114,013 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,884 |
112,684 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2015-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,312 |
116,760 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2016-01-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
169 |
103,888 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2016-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
53,287 |
155,181 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2017-01-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,631 |
165,178 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2017-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
48,750 |
202,829 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-08-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
118,500 |
3,277,601 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-08-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
50,000 |
25,000 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-08-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,400 |
3,274,201 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-08-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
11,900 |
3,262,301 |
0 |
- |
|
| BDSX |
Biodesix Inc |
|
• • – |
2022-12-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,619 |
31,619 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2016-01-21 |
4 |
S |
$6.80 |
$530 |
D/D |
(78) |
103,810 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2017-12-04 |
4 |
S |
$4.70 |
$635 |
D/D |
(135) |
197,770 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2018-02-02 |
4 |
S |
$5.13 |
$759 |
D/D |
(148) |
197,622 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2016-03-02 |
4 |
S |
$4.87 |
$765 |
D/D |
(157) |
153,639 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2016-05-02 |
4 |
S |
$5.79 |
$782 |
D/D |
(135) |
153,140 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2017-11-02 |
4 |
S |
$7.24 |
$977 |
D/D |
(135) |
199,174 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2015-12-03 |
4 |
S |
$7.71 |
$1,018 |
D/D |
(132) |
104,047 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2015-06-04 |
4 |
AS |
$9.81 |
$1,030 |
D/D |
(105) |
107,060 |
0 |
- |
|
90 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
